By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Pepiniere Sante Cochin
29 rue du Faubourg Saint Jacques
Paris    75014  France
Phone: 01-55-426200 Fax: 01-55-426201


Company News
PHARNEXT's Pleotherapy Shows Synergistic Effects With PXT-864 In Alzheimer's Disease Through Preclinical Data Published In Nature's Scientific Reports 1/8/2015 8:02:35 AM
PHARNEXT Announces Pleotherapy Proof Of Concept In Charcot-Marie-Tooth Disease Type 1A Through Two Peer-Reviewed Publications 12/18/2014 7:46:36 AM
PHARNEXT And The Hereditary Neuropathy Foundation Collaborate To Increase Awareness Of Charcot-Marie-Tooth Disease 9/16/2014 8:16:15 AM
Ipsen (IPN.PA) Joins PHARNEXT's Board Of Directors 6/30/2014 9:23:00 AM
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014 6:17:34 AM
PHARNEXT Raises an Additional €8 Million for Its PleotherapyTM Platform Applied to the Treatment of Charcot-Marie Tooth Disease and Alzheimer's Disease 2/9/2012 6:50:15 AM
PHARNEXT Has Completed Patient Recruitment for Its Phase II Clinical Trial of PXT3003 (the Company's First Pleodrug™) in Charcot-Marie-Tooth Disease 11/22/2011 10:42:23 AM
PHARNEXT Announces a €2.5 Million Round of Financing 9/8/2011 6:48:38 AM
PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the First Drug Generated by Its Pleotherapy(TM) Technology 12/3/2010 8:50:25 AM
OSEO Awards a €10.4 Million Funding Package to PHARNEXT, BioSystems International, Bordeaux Hospital (CMRR1), University Bordeaux Segalen and INSERM 11/18/2010 2:09:43 PM